deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT03036839

Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease (ESRD)

A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects With Genotype 1, 4, 5 and 6 Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease

Sponsor: Gilead Sciences

Interventions LDV/SOF
Updated 22 times since 2017 Last updated: Feb 18, 2020 Started: Jun 27, 2017 Primary completion: Nov 22, 2018 Completion: Feb 14, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03036839, this PHASE2 trial focuses on Hepatitis C Virus Infection and remains completed. Sponsored by Gilead Sciences, it has been updated 22 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jul 2017 · 3 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Feb 2018 · 31 days · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Jul 2019 · 4 months · monthly snapshot~Jul 2019 – ~Jan 2020 · 6 months · monthly snapshot~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

22 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE2

Show 17 earlier versions
  1. Jan 2020 — Apr 2020 [monthly]

    Completed PHASE2

  2. Jul 2019 — Jan 2020 [monthly]

    Completed PHASE2

  3. Mar 2019 — Jul 2019 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  4. Jan 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  7. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  8. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE2

  9. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE2

  10. Jan 2018 — Feb 2018 [monthly]

    Recruiting PHASE2

  11. Dec 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  12. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  13. Sep 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  14. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  15. Jul 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

  16. Apr 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE2

  17. Feb 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gilead Sciences
Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .